University of Notre Dame Endowment
The University of Notre Dame is a private Catholic institution located in South Bend, Indiana, renowned for its commitment to academic excellence, faith, and research. Offering a diverse array of undergraduate, graduate, and professional degree programs across fields such as business, engineering, humanities, and sciences, Notre Dame fosters a vibrant community that promotes intellectual development and innovation. The university's endowment fund is managed by its board of trustees, with investment earnings supporting essential initiatives such as scholarships, fellowships, endowed faculty positions, academic programs, and library collections. This endowment plays a crucial role in sustaining the university's mission and enhancing its educational offerings.
2 past transactions
Torigen Pharmaceuticals
Venture Round in 2022
Torigen Pharmaceuticals is a company dedicated to advancing cancer care solutions for companion animals. Founded in 2013 by Ashley Kalinauskas and Mark Suckow, the company is based in Farmington, Connecticut. Torigen focuses on developing innovative immunotherapy treatments, including an experimental autologous cancer vaccine that activates the immune system to target specific tumor-associated antigens on cancer cells. This approach aims to enable veterinarians to detect and treat cancer in animals more effectively, reducing the reliance on invasive surgeries and chemotherapy. By leveraging existing scientific research, Torigen seeks to improve outcomes for pets diagnosed with cancer, enhancing their quality of life through novel therapeutic strategies.
AgenDx Biosciences
Seed Round in 2018
AgenDx Biosciences is an early-stage molecular diagnostics company focused on developing a groundbreaking platform for cost-effective molecular diagnostics. This innovative technology enables rapid, lab-quality testing with a quick sample-to-answer turnaround, transforming disease detection and treatment. The platform supports a variety of nucleic acid-based tests for infectious diseases, cancer, and chronic conditions such as cardiovascular disease and arthritis. Initially, AgenDx aims to validate its technology by creating tests to assist physicians in making treatment decisions for pancreatic cancer. Designed for use by untrained personnel in clinical settings near patients, the platform utilizes a disposable cartridge for sample collection and an automated control system to run tests. Results are displayed clearly and can be transmitted easily, with the system capable of processing various biological samples, including blood, saliva, and tissue.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.